Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older at the time of joining the study.
• People who have given written consent to participate.
• People with liver cancer (hepatocellular carcinoma, or HCC) that has spread locally, to other parts of the body, or cannot be removed by surgery, confirmed by biopsy or by standard diagnostic guidelines.
• People whose liver cancer got worse during or after a previous treatment that combined an immunotherapy drug with another type of cancer medication (such as a VEGF-blocking antibody, a targeted therapy pill, or a different immunotherapy drug), or whose cancer came back within 6 months of finishing immunotherapy given before or after surgery.
• People who have at least one measurable area of cancer that has not been treated with local procedures, or that has grown again after a previous local treatment.
• People whose liver function and physical condition fall within acceptable ranges as measured by standard medical scoring tools (Child-Pugh score of 5–7 and ECOG performance score of 2 or below).
• People with a chronic hepatitis B infection whose virus levels are low (below 100 IU/mL at screening) and who are already taking antiviral medication.
• People expected to live for at least 12 weeks.
• People whose blood counts, liver enzyme levels, and kidney function meet specific minimum standards set out in the trial protocol.
• People of childbearing potential who have a negative pregnancy test within 7 days before starting the trial.
• People who are willing and able to follow all trial requirements, including attending scheduled visits, using required contraception, and completing follow-up.

Who may not be able to join:

• People with certain rare subtypes of liver cancer, specifically fibrolamellar HCC, sarcomatoid HCC, or a mixed liver-bile duct cancer.
• People who are on a waiting list for a liver transplant or who have very advanced liver disease.
• People with a history of heart disease, or who have had significant gastrointestinal bleeding within 4 weeks before starting the trial.
• People who have had a blood clot or stroke (including mini-strokes) or a pulmonary embolism within the 6 months before starting the trial (a clot in a specific small liver vein may be an exception — confirm with trial site).
• People who have or have had a second type of cancer, unless it was a fully treated minor skin cancer or a non-invasive cervical condition.
• People with a weakened immune system, including those known to be HIV positive.
• People who have taken part in another clinical trial with an experimental treatment within the past 30 days (or longer, depending on the previous trial medication — confirm with trial site).
• People with certain other health conditions or circumstances that the trial doctor believes could affect safety or results, including: a history of a specific type of lung inflammation; both hepatitis B and hepatitis C infections at the same time; known pancreas inflammation; active tuberculosis; any other active serious infection requiring systemic treatment; a history of organ or tissue transplant; a condition requiring immune-suppressing medication taken within 7 days before starting the trial; an active autoimmune disease requiring systemic treatment in the past 3 months, or a severe autoimmune history (though some conditions such as vitiligo, stable thyroid conditions, type 1 diabetes, and mild skin conditions managed without treatment are exceptions — confirm with trial site); a live vaccine received within 30 days before starting treatment; or brain or spinal cord metastases (spread of cancer to the central nervous system), unless treatment is complete, the person has no symptoms, and no steroid medication has been needed for at least 6 weeks — confirm with trial site.
• People taking medications known to interfere with the drugs used in this trial.
• People receiving any other active cancer treatment not specified by this trial.
• People who have received any other experimental treatment within 28 days of joining the study.
• People who are pregnant, breastfeeding, or people of reproductive potential who are not using an effective method of contraception as defined by the trial protocol.
• People with a significant history of not following medical treatment plans, or who are unable to give reliable informed consent.

Important: Always verify eligibility with the trial site directly before applying.